Approaching Treatment Sequencing In Heavily Pretreated Patients

EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer

EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer

EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer

EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer

EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer

EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing

EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

EP: 8.The Role of Novel Targeted Therapies

EP: 9.The Use of PARP Inhibitors in Ovarian Cancer

EP: 10.Earlier Introduction of Antibody-Drug Conjugates

Now Viewing

EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients

EP: 12.Single-Agent Vs Combination Regimens

EP: 13.The Potential Impact of Investigational Therapies

EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer

EP: 15.Overcoming Payer-Related Barriers for Optimal Care in Patients With Ovarian Cancer

EP: 16.The Importance of Multidisciplinary Collaboration in the Management of Ovarian Cancer

EP: 17.Streamlining Biomarker-Driven Therapy Decisions to Prevent Delays

EP: 18.The Effect of Adverse Event Profiles on Treatment Decisions

EP: 19.Evaluating Long-Term Safety Considerations for Targeted Therapies in Ovarian Cancer

Video content is prompted by the following:

Approaches to Treatment, Sequencing, and Heavily Pretreated Patients With Novel Agents

Key Discussion Points:

• Clinical Trial Access and Patient Referral
• Dr Moore emphasized the importance of seeking out clinical trials for platinum-resistant patients

• She highlighted multiple antibody-drug conjugates (ADCs) currently in clinical trials showing approximately 50% response rates

• Recommendation to refer patients early before administering standard therapies like pegylated liposomal doxorubicin, gemcitabine, or topotecan
• Biomarker Testing
• Essential testing for folate receptor and HER2 expression immediately upon platinum resistance

• Comprehensive molecular testing recommended for all patients

• Early testing enables access to targeted therapies through clinical trials
• Collaborative Care Networks
• Dr Moore advocated for building relationships with trial centers for patient referrals

• Importance of communication between community oncologists and academic centers with open trials

• Focus on preventing exclusion from promising trials due to prior therapy

Notable Insights:

“Reach out early. Once someone’s platinum resistant, make sure they’re tested for folate. Make sure they’re tested for HER2...make sure you’ve got molecular testing done by whatever platform you want to do.”

“Find a local friend that has trials open and just run things by them so we can get patients access to these medications that are actually working.”